For Immediate Release: May 7, 2015

Mary Kuramoto
513-579-9911 x2523

Medpace to speak at Outsourcing in Clinical Trials – Europe Topic: Central Lab Innovation in Patient Centric Clinical Trials

CINCINNATI, OH — (May 7, 2015) – Medpace Director, Malcolm McIntyre, will present at the 5th Outsourcing in Clinical Trials – Europe in Dusseldorf, Germany. Mr. McIntyre will present the topic, “Innovation in Patient Centric Clinical trials – A Quality driven approach by global labs.” The session will take place on Wednesday, May 20 from 10:30 am -11:00 am.

Mr. McIntyre will discuss a new paradigm in the role of measurable quality for central labs. The session will highlight the “added value” that can be leveraged by global labs when applying a quality and innovative approach to each patient visit. Examples of current and future innovations that embrace a “patient-centric approach” will be discussed including:

  • Building quality relations with sites and the importance of patient-friendly service
  • Enhancing the patient experience, enrolment, recruitment and retention, and reducing costs
  • Enhanced science and biomarkers driving faster, smarter patient stratification
  • Web-based portals to enhance the site experience and improve supplies management


Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management. For more information visit the Medpace website at: